Clinical trial · Observational
Splenic Artery Infusion Chemotherapy vs Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer
Efficacy and Safety of Splenic Artery Infusion Chemotherapy Compared With Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer: A Real-World Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic body and tail cancers are frequently diagnosed at an advanced stage and are associated with poor prognosis. Systemic chemotherapy remains the standard treatment for unresectable advanced pancreatic cancer, but its effectiveness is often limited by systemic toxicity and suboptimal intratumoral drug concentration. Splenic artery infusion chemotherapy (SAIC) is a regional treatment strategy that delivers chemotherapeutic agents directly into the arterial supply of the pancreatic body and tail, potentially increasing local drug concentration while reducing systemic exposure. However, clinical evidence comparing SAIC with conventional systemic chemotherapy in patients with advanced pancreatic body and tail cancer remains limited. This retrospective real-world study aims to compare the efficacy and safety of SAIC and systemic chemotherapy in patients with advanced pancreatic body/tail cancer treated at Sun Yat-sen Memorial Hospital. Clinical data from patients treated between January 2020 and December 2024 will be analyzed. Survival outcomes including overall survival (OS) and progression-free survival (PFS), radiological tumor response, biochemical response, surgical conversion rate, and treatment-related adverse events will be evaluated. The findings of this study may provide evidence to support the potential clinical value of splenic artery infusion chemotherapy as an alternative treatment strategy for patients with advanced pancreatic body/tail cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer (Unresectable) | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- From the start of treatment until death or the last follow-up visit; the follow-up cutoff date is December 31, 2025
- description
- Overall survival (OS) was defined as the time interval from the first administration of splenic artery infusion chemotherapy (SAIC) or systemic chemotherapy to death from any cause or the date of last follow-up.
Secondary outcomes (1)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From the start of treatment until disease progression or death; the follow-up cutoff date is December 31, 2025
- description
- Progression-free survival (PFS) was defined as the time interval from the start of treatment to the first disease progression (imaging/clinically confirmed) or death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:Age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; Pathologically confirmed locally advanced adenocarcinoma originating from the body or tail of the pancreas, or carcinoma with oligometastases to the liver; Adequate baseline organ and bone marrow function; Exclusion Criteria:Presence of other concurrent malignant tumors or autoimmune diseases; Receipt of fewer than two cycles of SAIC/systemic chemotherapy; Incomplete clinical data or loss to follow-up;
References
Publications (0)
Data not yet available